SPC25 and neoplasm: Low expression of NDC80 and SPC25 was also associated with favorable OS in multivariate analysis when adjusted for radiation therapy history, targeted therapy history, neoplasm status, TNM stage and residual tumors (log-rank P = 0.032, HR=0.635, 95%CI = 0.419 - 0.962; log-rank P = 0.047, HR=0.635, 95%CI = 0.434 - 0.995, respectively).